tetano
Editor, Senior Moderator
Brain Behav Immun Health
. 2021 Dec;18:100381.
doi: 10.1016/j.bbih.2021.100381. Epub 2021 Oct 30.
The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
M D Maldonado[SUP] 1 [/SUP], J Romero-Aibar[SUP] 2 [/SUP]
Affiliations
Abstract
Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection.
Methods: Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic.
Results: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV).
Discussion: The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency.
Keywords: APC, Professional antigen presenting cells. COVID-19; Angiotensin-Converting Enzyme Inhibitor. RT-PCR, Reverse transcriptase polymerase chain reaction. S protein: Transmembrane spike glycoprotein. SARS-CoV-2; Coronavirus Disease 2019. HLA, Human leukocyte antigens. IACE; Herpes zoster infection; Immune system; Severe Acute Respiratory Syndrome Coronavirus. VZV, Herpes virus varicella zoster; The anti-SARS-CoV-2 vaccines; mRNA-based vaccines.
. 2021 Dec;18:100381.
doi: 10.1016/j.bbih.2021.100381. Epub 2021 Oct 30.
The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
M D Maldonado[SUP] 1 [/SUP], J Romero-Aibar[SUP] 2 [/SUP]
Affiliations
- PMID: 34746880
- PMCID: PMC8556178
- DOI: 10.1016/j.bbih.2021.100381
Abstract
Background: To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection.
Methods: Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic.
Results: Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV).
Discussion: The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency.
Keywords: APC, Professional antigen presenting cells. COVID-19; Angiotensin-Converting Enzyme Inhibitor. RT-PCR, Reverse transcriptase polymerase chain reaction. S protein: Transmembrane spike glycoprotein. SARS-CoV-2; Coronavirus Disease 2019. HLA, Human leukocyte antigens. IACE; Herpes zoster infection; Immune system; Severe Acute Respiratory Syndrome Coronavirus. VZV, Herpes virus varicella zoster; The anti-SARS-CoV-2 vaccines; mRNA-based vaccines.